Changzhou Tongshu Biotechnology raised $78 million in a C round to support its gene testing products for cancer diagnoses, which are based on multiple innovative platforms. Founded in 2016, Tongshu Gene has developed IVD products that use ctDNA for early cancer screening tests. It will use the capital to continue developing its products and to build direct sales channels to more than 500 tertiary hospitals. The round was led by GL Capital Group, Broad Vision Funds and Oceanpine Capital. It included new investors Jinyuan Capital, Haichuang Fund of Funds and Yinhe Yuanhui Investment. More details.... Share this with colleagues: // //